Skip to main content

Table 4 Adverse effects (any grades) of immune checkpoint inhibitors after pemetrexed treatment failure

From: High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study

Adverse effects Long-term
administration
( n = 11)
Intermediate-term
administration
( n = 16)
Short-term
administration
( n = 55)
irAE 5 (45.5%) * 3 (18.8%) 10 (18.2%)
ILD 4 (36.3%) 2 (12.5%) 2 (3.6%)
Others 1 (9.1%) 1 (6.3%) 9 (16.4%)
  1. irAE immune-related adverse events, ILD interstitial lung disease
  2. *: P < 0.05 (Chi-square test)